Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hyun, Hakjun | - |
dc.contributor.author | Choi, Min Joo | - |
dc.contributor.author | Heo, Jung Yeon | - |
dc.contributor.author | Seo, Yu Bin | - |
dc.contributor.author | Nham, Eliel | - |
dc.contributor.author | Yoon, Jin Gu | - |
dc.contributor.author | Seong, Hye | - |
dc.contributor.author | Noh, Ji Yun | - |
dc.contributor.author | Cheong, Hee Jin | - |
dc.contributor.author | Kim, Woo Joo | - |
dc.contributor.author | Choi, Ju-Yeon | - |
dc.contributor.author | Lee, Young Jae | - |
dc.contributor.author | Lee, Hye Won | - |
dc.contributor.author | Kim, Sung Soon | - |
dc.contributor.author | Kim, Byoungguk | - |
dc.contributor.author | Song, Joon Young | - |
dc.date.accessioned | 2022-08-02T02:40:10Z | - |
dc.date.available | 2022-08-02T02:40:10Z | - |
dc.date.issued | 2022-07 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.issn | 1598-6357 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61248 | - |
dc.description.abstract | Background As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated. Method This prospective cohort study was conducted between June 2021 and January 2022 at two university hospitals in South Korea. Healthy adults who were scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main outcomes included anti-spike (S) IgG antibody and neutralizing antibody responses, S-specific T-cell responses (interferon-γ enzyme-linked immunospot assay), solicited adverse events (AEs), and serious AEs. Results Fifty participants aged ≥ 19 years were included in the study. Geometric mean titers (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 ± 3.0 U/mL at 3–4 weeks, 55.7 ± 2.4 U/mL at 5–8 weeks, and 81.3 ± 2.5 U/mL at 10–12 weeks after vaccination. GMTs of 50% neutralizing dilution (ND50) against WT SARS-CoV-2 were 164.6 ± 4.6 at 3-4 weeks, 313.9 ± 3.6 at 5–8 weeks, and 124.4 ± 2.6 at 10–12 weeks after vaccination. As for the S-specific T-cell responses, the median number of spot-forming units/106 peripheral blood mononuclear cell was 25.0 (5.0–29.2) at baseline, 60.0 (23.3–178.3) at 5-8 weeks, and 35.0 (13.3–71.7) at 10–12 weeks after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and fever (50%). Most AEs were grade 1–2, and resolved within two days. Conclusion Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5–8 weeks and rather decrease at 10–12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한의학회 | - |
dc.title | Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3346/jkms.2022.37.e210 | - |
dc.identifier.scopusid | 2-s2.0-85133745111 | - |
dc.identifier.wosid | 000826312400003 | - |
dc.identifier.bibliographicCitation | Journal of Korean Medical Science, v.37, no.27, pp 1 - 9 | - |
dc.citation.title | Journal of Korean Medical Science | - |
dc.citation.volume | 37 | - |
dc.citation.number | 27 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002859934 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | Vaccines | - |
dc.subject.keywordAuthor | Adenovirus Vector | - |
dc.subject.keywordAuthor | Humoral Immunity | - |
dc.subject.keywordAuthor | Cellular Immunity | - |
dc.subject.keywordAuthor | Adverse Events | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.